Clinical Analysis And Prognostic Significance Of Lymphoma-associated Hemophagocytosis In Peripheral T-cell Lymphoma

Objectives:This study aims to retrospectively analyze the clinical characteristics, treatments, and prognosis of aggressive peripheral T cell lymphoma(PTCL) patients with a lymphoma-associated hemophagocytosis syndrome(LAHS).Methods:We compared the clinical features and the overall survival (OS) rates of159PTCL patients with and without LAHS as well as the treatment outcomes of these patients with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or intensive chemotherapy regimens.Results:We observed that in23%(36/159) patients PTCL was associated with LAHS. Different subtypes of PTCL in LAHS patients were diagnosed and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) was the main subtype (78%). The median survival rates of the LAHS and non-LAHS groups were3months and16months, respectively. The elevated rates of serum β2-microglobulin (β2-MG), ferritin, fasting triglycerides, and hypofibrinogen levels were higher in the LAHS group, so were bone marrow involvement, liver dysfunction, hepatosplenomagely and B symptoms. Three patients who were treated with a plasma exchange had a longer survival time. There was no statistically significant difference in the OS rates between the intensive chemotherapy and CHOP regimen groups (P>0.05). Conclusion:PTCL patients with LAHS had a poorer prognosis. Awareness of the clinical symptoms and laboratory findings are crucial in order to diagnose LAHS in an early stage and repeated biopsies of multiple bone marrows from different locations in those patients without enlargement of superficial lymph nodes are necessary to improve the diagnosis. Intensive chemotherapy due to its severe toxicity was not obviously advantageous for the OS rate compared to the CHOP regimen.